Semaglutide is a GLP-1 receptor agonist originally approved for managing Type 2 diabetes. Recent clinical trials have shown its efficacy in weight loss, leading to its approval for chronic weight management in individuals with obesity. However, semaglutide use solely for weight loss has sparked debate within the medical community. This controversy encompasses several critical aspects, […]